Vitamin C is one of the most sensitive cosmetic active ingredients. To avoid its degradation, its encapsulation into biobased carriers such as dendrimers is one alternative of interest. In this work, we wanted to evaluate the potential of two biobased glycerodendrimer families (GlyceroDendrimers-Poly(AmidoAmine) (GD-PAMAMs) or GlyceroDendrimers-Poly(Propylene Imine) (GD-PPIs)) as a vitamin C carrier for topical application. The higher encapsulation capacity of GD-PAMAM-3 compared to commercial PAMAM-3 and different GD-PPIs, and its absence of cytotoxicity towards dermal cells, make it a good candidate. Investigation of its mechanism of action was done by using two kinds of biomimetic models of stratum corneum (SC), lipid monolayers and liposomes. GD-PAMAM-3 and VitC@GD-PAMAM-3 (GD-PAMAM-3 with encapsulated vitamin C) can both interact with the lipid representatives of the SC lipid matrix, whichever pH is considered. However, only pH 5.0 is suggested to be favorable to release vitamin C into the SC matrix. Their binding to SC-biomimetic liposomes revealed only a slight effect on membrane permeability in accordance with the absence of cytotoxicity but an increase in membrane rigidity, suggesting a reinforcement of the SC barrier property. Globally, our results suggest that the dendrimer GD-PAMAM-3 could be an efficient carrier for cosmetic applications.
Leishmaniasis and toxoplasmosis are neglected parasitic diseases that remain major global health concerns due to limited therapeutic options, drug toxicity, and emerging resistance. In this context, the development of new antiparasitic agents based on natural product scaffolds is highly relevant. Totarol, a naturally occurring abietane-type diterpene isolated from Tetraclinis articulata, was used as a starting scaffold for hemisynthetic modification. A series of totarol-derived functionalized ketones, including α-bromoketone (4) and chalcone derivatives (5a–g), was synthesized and fully characterized by NMR, IR, and HRMS analyses. The compounds were evaluated for their in vitro antiparasitic activity against Leishmania major and Toxoplasma gondii. Compound 4 showed the highest activity, with half-maximal inhibitory concentration (IC50) values of 3.2–5.3 µM against Leishmania major and 6.1 µM against T. gondii. However, compound 4 showed none strong host–cell selectivity, with selectivity indices of 0.79–1.5. Docking against L. major pteridine reductase 1 (PTR1) gave a Glide XP score of −5.3 kcal/mol, and the modeled complex persisted during a 100 ns molecular dynamics simulation. These computational results generate a hypothesis for antileishmanial activity without demonstrating PTR1 inhibition or explaining T. gondii activity. The active structures require substantial optimization of selectivity before consideration as antiparasitic candidates.